<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2048">
  <stage>Registered</stage>
  <submitdate>14/07/2008</submitdate>
  <approvaldate>14/07/2008</approvaldate>
  <nctid>NCT00716300</nctid>
  <trial_identification>
    <studytitle>High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome</studytitle>
    <scientifictitle>Functional Studies of High Density Lipoprotein in the Metabolic Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DC-HDL2008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic Syndrome X</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - obese and insulin resistant subjects

2 - lean and normolipidaemic subjects

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>MetS :the presence of at least three of the following:

          -  waist circumference &gt; 102 cm, triglycerides &gt; 1.7 mmol/L, HDL cholesterol &lt; 1.05
             mmol/L

          -  blood pressure = 130/ = 85 mmHg

          -  fasting glucose &gt; 6.1 mmol/L

        Lean control:

          -  BMI &lt; 25 kg/m2

          -  waist circumference &lt; 102 cm

          -  triglycerides &lt; 1.0 mmol/L

          -  HDL-cholesterol &gt; 1.3 mmol/L</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  subjects with plasma LDL-cholesterol &gt; 5 mmo/L

          -  diabetes mellitus (defined by oral glucose tolerance test)

          -  genetic hyperlipidaemia (e.g. FH)

          -  consumption of &gt; 30 g alcohol/day

          -  apolipoprotein E2/E2 genotype

          -  macroproteinuria

          -  creatinaemia ( &gt; 120 umol/L)

          -  hypothyroidism

          -  hepatic dysfunction (AST or ALT &gt; 2x ULN)

          -  major systemic illness and use of steroids or other agents that may influence lipid
             metabolism

          -  cardiovascular event within the past 6 months

          -  subjects on hypocaloric diets

          -  anaemia; any significant illness that in the opinion of reviewing physician would bear
             on the study (e.g. heart murmur or psychiatric conditions)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2009</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>University of Western Australia - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to examine the kinetic, anti-oxidant, anti-inflammatory and cellular
      cholesterol efflux properties of high-density lipoprotein (HDL) in subjects with the
      metabolic syndrome (MetS) and lean individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00716300</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerald F Watts, MBBS</name>
      <address>The University of Western Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Dick C Chan, PhD</name>
      <address />
      <phone>61-8-92240268</phone>
      <fax />
      <email>dick.chan@uwa.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>